



(22) **Date de dépôt/Filing Date:** 2006/12/21

(41) **Mise à la disp. pub./Open to Public Insp.:** 2007/07/05

(45) **Date de délivrance/Issue Date:** 2017/02/28

(62) **Demande originale/Original Application:** 2 634 915

(30) **Priorité/Priority:** 2005/12/22 (US60/753,497)

(51) **Cl.Int./Int.Cl.** **A61K 47/02** (2006.01),  
**A61K 33/00** (2006.01), **A61P 25/28** (2006.01)

(72) **Inventeurs/Inventors:**  
BOULANGER, WILLIAM, US;  
AZHIR, ARASTEH ARI, US

(73) **Propriétaire/Owner:**  
NEURALTUS PHARMACEUTICALS, INC., US

(74) **Agent:** NORTON ROSE FULBRIGHT CANADA  
LLP/S.E.N.C.R.L., S.R.L.

(54) **Titre :** FORMULATIONS DE CHLORITE ET LEURS PROCEDES DE PREPARATION ET D'UTILISATION

(54) **Title:** CHLORITE FORMULATIONS, AND METHODS OF PREPARATION AND USE THEREOF

(57) **Abrégé/Abstract:**

Described herein are pharmaceutical compositions comprising (a) an aqueous solution comprising sodium chlorite and comprising chlorate ions, wherein the weight ratio of chlorite:chlorate is greater than 100:1.5, and the concentration of chlorite is at least 60 mM; (b) phosphate buffer; and (c) a pharmaceutically acceptable excipient; wherein the composition is a sterile intravenous solution having a pH between 7 and 9.5. Also described herein are such pharmaceutical compositions for use in treating macrophage-associated neurodegenerative diseases.

